AI-Designed Mini-Proteins Replace Antibodies as TROP2-Targeting Drug Carriers for Solid Tumors
- Deep-learning design produced a small protein binder against the tumor antigen TROP2, avoiding animal immunization and antibody screening.
- The binder showed good specificity and thermal stability, and partial diffusion sharpened its affinity by roughly sixty-fold.
- Attaching the microtubule-disrupting payload VcMMAE yielded mini-protein drug conjugates that selectively kill TROP2-positive cancer cells.
- Activity was assessed in cell lines, organoids and mouse xenografts.
💡 Points Based on the abstract
A de novo binder skips immunization, but an ADC carrier lives or dies on pharmacokinetics: without an Fc or albumin-binding handle, a mini-protein clears through the kidney fast, and a vcMMAE payload will raise renal and hydrophobicity-driven uptake concerns. I'd want half-life, kidney accumulation and TROP2-negative tissue data, plus a head-to-head against sacituzumab-type ADCs, before calling this an antibody replacement.
📄 Paper · Journal of Medicinal Chemistry (ACS) ↗ Design of High-Affinity Mini-Protein Drug Conjugates Targeting TROP2